Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate

• Drug: Etanercept
  
  Etanercept 50 mg once-weekly
• Drug: Placebo
  
  Etanercept placebo once-weekly

• Experimental: Group A
  
  Subjects who are mAb ADA positive
  Intervention: Drug: Etanercept
• Experimental: Group B
  
  Subjects who are mAb ADA negative
  Intervention: Drug: Etanercept
• Placebo Comparator: Group C
  
  Subjects who are mAb ADA positive
  Intervention: Drug: Placebo
• Placebo Comparator: Group D
  
  Subjects who are mAb ADA negative
  Intervention: Drug: Placebo

Inclusion Criteria:

1. Met the 1987 ACR Revised Criteria for RA
2. A history of inadequate response to infliximab or adalimumab in combination with methotrexate.
3. A stable dose of oral methotrexate for at least 6 weeks before the baseline visit.

Exclusion Criteria:

1. ACR functional class IV
2. Prior treatment with etanercept; both infliximab and adalimumab; or any immunosuppressive biologic agent other than infliximab or adalimumab.
3. Discontinuation of infliximab or adalimumab for a primary reason other than inadequate efficacy response.